Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance

Halozyme Therapeutics Inc. Common StockTrade
Charles Schwab Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

Halozyme Therapeutics Inc. Common Stock vs Charles Schwab Corporation Common Stock — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Charles Schwab Corporation Common Stock trades at $96.93 (market cap $167.52B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 13.3× Halozyme Therapeutics Inc. Common Stock's market cap, and Charles Schwab Corporation Common Stock pays a 1.32% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Charles Schwab Corporation Common Stock for 85 Days on average.

HALOSCHW
Market Cap
$12.58B$167.52B
Volume
2,179,2786,554,126
Sector
HealthFinancials
52-Week High
$115.22$113.65
52-Week Low
$61.63$85.35
Typical Hold Time
1 Days85 Days
Enterprise Value
$14.49B$153.97B
Dividend Yield
—1.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Halozyme Therapeutics Inc. Common Stock

No Aura AI signal available yet.

Charles Schwab Corporation Common Stock

Charles Schwab (SCHW) trades at $96.70, up 1.17% with bearish technical signals but strong fundamentals. The company reported record quarterly revenue of $7.08 billion (The Motley Fool, 2026-09-29) and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains bullish with a $120.33 price target, representing 24% upside potential. Recent developments include dual listing on the Texas Stock Exchange and AI integration partnerships with Anthropic.

SCHW offers compelling value with a P/E of 17.64 and robust 38.79% net margin, though technical indicators signal near-term caution. The stock faces risks from narrowing interest spreads and market volatility, but strong earnings momentum and institutional support provide solid foundation for long-term growth.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HALO

No sentiment data available yet.

SCHW
100% Buy0% Sell
Avg holding period · 85 Days

About Halozyme Therapeutics Inc. Common Stock

Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.

Read more on HALO →

About Charles Schwab Corporation Common Stock

Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.

Read more on SCHW →